Skip to search formSkip to main contentSkip to account menu

MS 209

Known as: MS-209, MS209 
National Institutes of Health

Related topics

Related topics

2 relations
Dofequidar Fumarate

Broader (1)

dofequidar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
MS-209 Schering.
MS-209, a quinolone-derived sphingomyelin synthase inhibitor that blocks P-glycoprotein and multidrug resistance-associated… 
2004
2004
Relationship between multidrug resistant gene expression and multidrug resistant-reversing effect of MS-209 in various tumor cells
MS-209 is a novel quinoline compound which can overcome multidrug resistance (MDR) both in vitro and in vivo, while having a low… 
2002
2002
P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel
Abstract.Purpose: Recent studies in humans and mice have demonstrated that intestinal P-glycoprotein plays a causative role in… 
2002
2002
Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging
Abstract. MS-209 is a newly synthesised multidrug-resistance (MDR)-reversing agent with few side-effects. In this study, we… 
Review
2001
Review
2001
All-trans Retinoic Acid (ATRA) Differentiates Acute Promyelocytic Leukemia Cells Independently of P-Glycoprotein (P-gp) Related Multidrug Resistance
Here the relationship between all-trans retinoic acid (ATRA)-resistance and P-glycoprotein (P-gp)-associated multidrug resistance… 
Highly Cited
1999
Highly Cited
1999
Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells.
MS-209 is a novel quinoline derivative reversing P-glycoprotein-mediated multidrug resistance (MDR). We investigated the… 
1998
1998
Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil
Purpose and methods: To develop a clinically useful approach to circumvent P-glycoprotein (P-gp)-mediated multidrug resistance… 
1997
1997
Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
A novel quinoline compound, MS-209, was examined for its ability to reverse multidrug resistance (MDR) in several murine and… 
1997
1997
New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833
Abstract The emergence of multidrug resistance (MDR) is a major problem in cancer chemotherapy. Many compounds have been… 
1997
1997
Recovery of drug sensitivity by MS‐209, a new multidrug resistance‐reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line
Abstract: The efficacy of MS‐209, a quinoline derivative synthesized as a new multidrug resistance (MDR)‐reversing agent, was… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)